A Radnor biopharma firm saw its stock price skyrocket after the company posted positive late-stage clinical trial results for ...

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) released topline data from its pivotal Launch-HTN Phase 3 and pivotal Advance-HTN ...

Findings from a pair of studies in tough-to-treat hypertension establish Mineralys’ drug as a “derisked, almost-commercial ...

Primary endpoints of both Advance-HTN and Launch-HTN studies, using lorundrostat to treat patients with hypertension were met ...

Mineralys Therapeutics enjoyed a big stock bump after its aldosterone synthase inhibitor chalked up wins in two types of ...

Mineralys Therapeutics’s oral hypertension therapy, lorundrostat, has met the primary endpoint in two pivotal studies, ...

Mineralys Therapeutics said on Monday its lead drug significantly lowered blood pressure in patients with difficult-to-treat hypertension in late- and mid-stage trials.

Mineralys’ shares got a more than 50% boost Monday morning as new data showed its hypertension drug reduced blood pressure in ...

Mineralys Therapeutics (MYLS) priced an underwritten public offering of ~12.96M shares at a public offering price of $13.50 per share. The aggregate gross proceeds are expected to be ~$175M.

BofA Securities, Evercore ISI, Goldman Sachs & Co. LLC, Stifel and Wells Fargo Securities are acting as joint book-running managers for the offering. LifeSci Capital is acting as lead manager and H.C.

March 10 (Reuters) - Mineralys Therapeutics (MLYS.O), opens new tab said on Monday its lead drug significantly lowered blood pressure in patients with difficult-to-treat hypertension in late- and ...

Mineralys Therapeutics (MLYS) announced that it has commenced an underwritten public offering of $250M of shares of its common stock. Mineralys ...